Skip to content
OpenCapital
Get started

Cartesian Therapeutics, Inc. RNAC Q1 2026 earnings

Reported April 30, 2026 · Before market open

Revenue$78.0KMiss by $141.8K
EPS-$1.46Miss by $0.62
Revenue estimate$219.8K
EPS estimate-$0.84

Next report

Aug 6, 2026 (In 1 week)
Revenue estimate$179.7K
EPS estimate-$0.83

Versus estimates

Revenue

Q1 2026$78.0KMiss by $141.8K
Q4 2025$947.0KBeat by $796.7KQ3 2025$452.0KBeat by $351.8KQ2 2025$298.0KBeat by $120.4KQ1 2025$1.1MBeat by $412.5KQ4 2024$759.0KMiss by $241.0K

Diluted EPS

Q1 2026-$1.46Miss by $0.62
Q4 2025-$1.38Miss by $0.56Q3 2025-$1.38Miss by $0.57Q2 2025$0.50Beat by $1.26Q1 2025-$0.68Miss by $0.07Q4 2024-$0.59Beat by $0.19

Ask the moment Cartesian Therapeutics, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Cartesian Therapeutics, Inc. report Q1 2026 earnings?
Cartesian Therapeutics, Inc. (RNAC) reported Q1 2026 earnings on April 30, 2026 before market open.
What were Cartesian Therapeutics, Inc.'s Q1 2026 revenue and EPS?
Cartesian Therapeutics, Inc. reported revenue of $78.0K and eps of $-1.46 for Q1 2026.
Did Cartesian Therapeutics, Inc. beat estimates in Q1 2026?
Revenue missed the consensus estimate of $219.8K by $141.8K. EPS missed the consensus estimate of $-0.84 by $0.62.
How did Cartesian Therapeutics, Inc.'s Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 92.9% from $1.1M a year earlier and eps declined 114.7% from $-0.68.
Where can I find Cartesian Therapeutics, Inc.'s Q1 2026 SEC filings?
You can read the 8-K earnings release (0001453687-26-000081) and the 10-Q periodic report (0001453687-26-000082) directly on SEC EDGAR. The filing index links above go to sec.gov.